^
Association details:
| Biomarker: | Chr del(17p) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Regimen: | FCR (cyclophosphamide + fludarabine IV + Rituxan (rituximab)) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TEN-YEAR FOLLOW-UP OF 415 CLL PATIENTS TREATED WITH FLUDARABINE CYCLOPHOSPHAMIDE-BASED CHEMOIMMUNOTHERAPY IN THE FRONTLINE ARCTIC AND ADMIRE TRIALS, A COMPREHENSIVE ASSESSMENT OF PROGNOSTIC FACTORS
Published date:
05/12/2021
Excerpt:
CONTRADICTING EVIDENCE: FCR and FCM-R...PFS by pre-treatment prognostic factors revealed unmutated IGHV genes (UM-IGHV), 17p/11q deletion, TP53 mutations, CLL-IPI, %CD38+ cells, decreasing CD20 mean fluorescence intensity (MFI), %CD49d+ cells, CCR6 (MFI and %+ cells) and LAIR1 MFI to be associated with shortened PFS....A multivariable analysis of prognostic factors and MRD reveals the key prognostic factors for shortened OS to be age, MRD, d17p/TP53 mutation and CD49d.
Source:
Title:
TEN-YEAR FOLLOW-UP OF 415 CLL PATIENTS TREATED WITH FLUDARABINE CYCLOPHOSPHAMIDE-BASED CHEMOIMMUNOTHERAPY IN THE FRONTLINE ARCTIC AND ADMIRE TRIALS, A COMPREHENSIVE ASSESSMENT OF PROGNOSTIC FACTORS
Published date:
05/12/2021
Excerpt:
CONTRADICTING EVIDENCE: FCR and FCM-R...PFS by pre-treatment prognostic factors revealed unmutated IGHV genes (UM-IGHV), 17p/11q deletion, TP53 mutations, CLL-IPI, %CD38+ cells, decreasing CD20 mean fluorescence intensity (MFI), %CD49d+ cells, CCR6 (MFI and %+ cells) and LAIR1 MFI to be associated with shortened PFS....A multivariable analysis of prognostic factors and MRD reveals the key prognostic factors for shortened OS to be age, MRD, d17p/TP53 mutation and CD49d.
Secondary therapy:
mitoxantrone
Source:
Title:
Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group
Published date:
02/22/2021
Excerpt:
Between March 2009 and July 2012, we enrolled 107 patients considered ineligible for full-dose FCR...The median progression-free survival was 29 months, but was markedly longer in patients with mutated IGHV (median 53 months), especially in absence of del 11q or 17p (median 74 months). Low-dose FCR is a well-tolerated and effective first-line regimen for selected elderly/comorbid patients with CLL/SLL with favourable biology.
DOI:
10.1111/bjh.17373
